Etalanetug (E2814) in dominantly inherited Alzheimer's disease: An open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment

Authors

• Erica Andreozzi, Eisai Inc.
• Kanta Horie, Washington University School of Medicine in St. Louis
• Nicolas R Barthélemy, Washington University School of Medicine in St. Louis
• Brian A Gordon, Washington University School of Medicine in St. Louis
• Shaney Flores, Washington University School of Medicine in St. Louis
• Tammie L S Benzinger, Washington University School of Medicine in St. Louis
• Eric McDade, Washington University School of Medicine in St. Louis
• Randall J Bateman, Washington University School of Medicine in St. Louis
• et al.

Journal

Alzheimer's Research & Therapy

Publication Date

4-10-2026

Volume

18

Issue

1

First Page

87

Document Type

Open Access Publication

DOI

10.1186/s13195-026-02047-y

Rights and Permissions

Andreozzi, E., Yagi, T., Wildsmith, K. et al. Etalanetug (E2814) in dominantly inherited Alzheimer’s disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment. Alz Res Therapy 18, 87 (2026). https://doi.org/10.1186/s13195-026-02047-y This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Recommended Citation

Andreozzi, Erica; Horie, Kanta; Barthélemy, Nicolas R; Gordon, Brian A; Flores, Shaney; Benzinger, Tammie L S; McDade, Eric; Bateman, Randall J; and et al., "Etalanetug (E2814) in dominantly inherited Alzheimer's disease: An open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment." Alzheimer's Research & Therapy. 18, 1. 87 (2026).
https://digitalcommons.wustl.edu/oa_4/7323

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.